Detalhe da pesquisa
1.
Cardiovascular disease risk assessment and multidisciplinary care in prostate cancer treatment with ADT: recommendations from the APMA PCCV expert network.
World J Urol
; 42(1): 156, 2024 Mar 14.
Artigo
Inglês
| MEDLINE | ID: mdl-38483562
2.
Metastatic castration resistant prostate cancer patients' experience with Radium-223 treatment in Japan.
Future Oncol
; 20(12): 781-798, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38275149
3.
Clinical management of nonobstructive azoospermia: An update.
Int J Urol
; 31(1): 17-24, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-37737473
4.
Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data.
Int J Urol
; 2024 Feb 25.
Artigo
Inglês
| MEDLINE | ID: mdl-38402449
5.
Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide.
BMC Cancer
; 23(1): 214, 2023 Mar 07.
Artigo
Inglês
| MEDLINE | ID: mdl-36882764
6.
A high serum dehydroepiandrosterone concentration is a predictor of candidates for active surveillance in men with serum prostate-specific antigen < 10 ng/mL.
BMC Cancer
; 22(1): 1169, 2022 Nov 12.
Artigo
Inglês
| MEDLINE | ID: mdl-36371158
7.
Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis.
Jpn J Clin Oncol
; 52(5): 441-448, 2022 May 05.
Artigo
Inglês
| MEDLINE | ID: mdl-35229141
8.
Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan.
Int J Clin Oncol
; 27(2): 418-426, 2022 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-34779962
9.
Health-related quality of life with enzalutamide versus flutamide in castration-resistant prostate cancer from the AFTERCAB study.
Int J Clin Oncol
; 27(10): 1632-1643, 2022 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-35948732
10.
Administration of radium-223 and the prognosis in Japanese bone metastatic castration-resistant prostate cancer patients: A large database study.
Int J Urol
; 29(9): 1079-1084, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35976620
11.
Treatment strategies and outcomes in a long-term registry study of patients with high-risk metastatic hormone-naïve prostate cancer in Japan: An interim analysis of the J-ROCK study.
Int J Urol
; 29(9): 1061-1070, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-36018236
12.
Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN study.
Int J Urol
; 29(6): 533-540, 2022 06.
Artigo
Inglês
| MEDLINE | ID: mdl-35293030
13.
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
N Engl J Med
; 378(15): 1408-1418, 2018 Apr 12.
Artigo
Inglês
| MEDLINE | ID: mdl-29420164
14.
A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer.
World J Urol
; 39(9): 3323-3328, 2021 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-33644830
15.
A qualitative research study in Japan investigating patients' experience with metastatic castration-resistant prostate cancer: from diagnosis to decision for Ra-223 treatment.
Future Oncol
; 17(36): 5103-5118, 2021 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-34664992
16.
Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial.
Int J Clin Oncol
; 26(3): 578-590, 2021 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-33226524
17.
Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study.
Int J Urol
; 28(7): 765-773, 2021 07.
Artigo
Inglês
| MEDLINE | ID: mdl-33955599
18.
Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study.
Int J Urol
; 28(3): 280-287, 2021 03.
Artigo
Inglês
| MEDLINE | ID: mdl-33295007
19.
[Chemoprevention for Prostate Cancer-The Potential of Angiotensin â ¡ Receptor Blocker].
Gan To Kagaku Ryoho
; 48(12): 1435-1439, 2021 Dec.
Artigo
Japonês
| MEDLINE | ID: mdl-34911906
20.
BHD-associated kidney cancer exhibits unique molecular characteristics and a wide variety of variants in chromatin remodeling genes.
Hum Mol Genet
; 27(15): 2712-2724, 2018 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29767721